Rechercher
Journal Club
- nbidere
- 13 févr. 2023
- 1 min de lecture
Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy
Volume 35, Issue 1, 3 January 2023, Pages 84-100.e8
Highlights
• Integrated analysis systematically demonstrates the ferroptosis heterogeneity in TNBC
• LAR subtype of TNBC is hypersensitive to ferroptosis inducers, especially GPX4 inhibitors
• AR plays a dual role in regulating ferroptosis of LAR tumors•Combination of GPX4 inhibitors and immunotherapy is an option for LAR tumors
Comentarios